BLUEPRINT MEDICINES news, videos and press releases
For more news please use our advanced search feature.
BLUEPRINT MEDICINES - More news...
BLUEPRINT MEDICINES - More news...
- Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
- Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
- Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
- Blueprint Medicines to Present at Upcoming Investor Conferences
- The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist
- The Schall Law Firm Is Investigating Blueprint Medicines Corporation For Securities Fraud And Stockholders With Losses Are Invited To Contribute
- Investors Of Blueprint Medicines Corporation Are Informed By The Schall Law Firm About Ongoing Investigations Into Possible Securities Law Breaches
- Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Potential Securities Law Violations
- Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
- Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
- Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
- Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
- The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors In Blueprint Medicines Corporation
- Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
- At The Moment The Schall Law Firm Is Probing Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation
- Currently The Schall Law Firm Is Investigating Possible Securities Law Breaches For Shareholders Of Blueprint Medicines Corporation
- At Present The Schall Law Firm Is Probing Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation
- Currently The Schall Law Firm Is Investigating Possible Securities Law Breaches For Blueprint Medicines Corporation Investors
- Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
- Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
- Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
